Collins Stewart Starts Masimo Corp. (MASI) at Buy; Long-Term Bullishness Offsets Near-Term Concerns
Tweet
Share
E-mailGet Alerts MASI Hot Sheet
Price: $179.95 --0%
Rating Summary:
11 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
11 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Collins Stewart initiates coverage on Masimo Corp. (NASDAQ: MASI) with a Buy. PT $28.00.
Collins analyst says, "Masimo is a leading player in the multi-billion dollar noninvasive patient monitoring market. The majority of Masimo's revenue is derived from the $1 billion pulse oximetry market where it holds the number 2 position and is gaining share. The company's razor/razor blade business model, large installed base of monitors, and multi-year exclusive hospital contracts offer an enviable stream of recurring revenue. In addition, MASI can leverage its sizable customer base with the recent introduction of numerous novel technologies that address a combined $1.2 billion opportunity. While we acknowledge that soft hospital patient admissions provide a near-term risk to estimates, we believe this is mostly reflected in MASI's valuation and is offset by the company's favorable long-term opportunities."
For more ratings news on Masimo Corp. click here and for the rating history of Masimo Corp. click here.
Shares of Masimo Corp. closed at $22.65 yesterday.
Collins analyst says, "Masimo is a leading player in the multi-billion dollar noninvasive patient monitoring market. The majority of Masimo's revenue is derived from the $1 billion pulse oximetry market where it holds the number 2 position and is gaining share. The company's razor/razor blade business model, large installed base of monitors, and multi-year exclusive hospital contracts offer an enviable stream of recurring revenue. In addition, MASI can leverage its sizable customer base with the recent introduction of numerous novel technologies that address a combined $1.2 billion opportunity. While we acknowledge that soft hospital patient admissions provide a near-term risk to estimates, we believe this is mostly reflected in MASI's valuation and is offset by the company's favorable long-term opportunities."
For more ratings news on Masimo Corp. click here and for the rating history of Masimo Corp. click here.
Shares of Masimo Corp. closed at $22.65 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- Seaport Global Securities Starts ADI Global Distribution (ADIG) at Buy
- JPMorgan Assumes salesforce.com (CRM) at Overweight, 'Overblown Concerns'
Create E-mail Alert Related Categories
New CoverageRelated Entities
Collins StewartSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
